{"url_path":"/sec/ctxr/8-k/2026-06-01/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1506251/0001213900-26-063531-index.html","accession_number":"0001213900-26-063531","cik":"0001506251","ticker":"CTXR","issuer_name":"Citius Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1506251/0001213900-26-063531-index.html","primary_entity_key":"0001506251","primary_entity_name":"Citius Pharmaceuticals, Inc."},"word_count":53,"has_tables":true,"body_markdown":"** **\n\n**Item 8.01 Other Events.**\n\n** **\n\nOn June 1, 2026, our wholly-owned\nsubsidiary, Citius Oncology, Inc., issued a press release announcing the presentation of clinical data at the Annual Meeting of the American\nSociety of Clinical Oncology. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K."}